NCT07811869RecruitingPhase 3

A 52-week Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

Novartis Pharmaceuticals1 site in 1 country180 target enrollmentStarted: October 6, 2026Last updated: September 10, 2026

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 3
Status: Recruiting
Sponsor: Novartis Pharmaceuticals
Enrollment: 180
Locations: 1
Primary Endpoint: Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS)

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Detailed Description

This is a global, phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of remibrutinib in adult participants with severe CPUO.

The design includes 4 periods, for a total duration of up to 60 weeks:

Screening period: up to 4 weeks.
Double-blind treatment period (treatment period 1, TP1): 24 weeks of double-blind treatment with remibrutinib or matching placebo
Open-label treatment period (treatment period 2, TP2): 28 weeks of open-label treatment with remibrutinib. The participants randomized to the placebo arm will be switched to remibrutinib at Week 24.
Safety follow-up period: 4 weeks of treatment-free safety follow-up.

Study Design

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel
Primary Purpose: Treatment
Masking: Double (Participant, Investigator)

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Participant must be ≥ 18 years of age, at the time of signing the informed consent.
•Participants with chronic pruritus for at least 4 months prior to screening.
•Chronic pruritus considered of unknown origin as assessed by the investigator at baseline (e.g., excluding chronic pruritus related to primary dermatological or systemic conditions, neuropathic or psychogenic origin or secondary to drugs or other allergen exposures).
•Chronic pruritus must affect at least 2 of the following body areas: trunk, arms, or legs (cannot be unilateral and/or dermatomal in distribution).
•Participants with ongoing, severe chronic pruritus despite the use of emollients and who are candidates for systemic therapy.
•Participants must have severe itch defined by a WI-NRS ≥7 at screening; score scale ranges from 0 to 10; higher score indicates worse itch.
•Participants must have an average WI-NRS ≥7 over the 7 days prior to randomization/baseline visit.
•The average WI-NRS score over the preceding 7 days prior to the randomization/baseline visit will be calculated based on the daily WI-NRS scores (0-10).
•Participants must have PGIS of pruritus scored as 3 "severe" at screening and baseline visits.

Exclusion Criteria

•Any active skin conditions (e.g., atopic dermatitis, psoriasis, etc.) that may interfere with the assessment of CPUO.
•Known systemic condition(s) or medication(s) that are considered by the investigator to be the primary cause of current pruritus.
•Known or suspected infectious disease that is active, chronic or recurrent which precludes the participant from participating in the clinical trial as per Investigator´s assessment. These infectious diseases include but are not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis) and/or known or suspected HIV infection.
•History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
•Significant bleeding risk or coagulation disorders. History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal anti-inflammatory drugs (NSAIDs), that was clinically relevant (e.g., where intervention was indicated or requiring hospitalization or blood transfusion). Requirement for anti-platelet medication, except for acetylsalicylic acid up to 100 mg/d or clopidogrel up to 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopidogrel) is prohibited.
•History or current hepatic disease, including but not limited to, acute or chronic hepatitis, cirrhosis or hepatic failure or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.

Arms & Interventions

Placebo followed by remibrutinib

Experimental

Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib).

Intervention: Placebo (Drug)

Remibrutinib

Experimental

Remibrutinib film coated tablets

Intervention: Remibrutinib (Drug)

Placebo followed by remibrutinib

Experimental

Matching placebo. At the Week 24 visit, all participants will receive active treatment (remibrutinib).

Intervention: Remibrutinib (Drug)

Outcomes

Primary Outcomes

Proportion of participants achieving ≥4 point reduction from baseline in Worst itch Numerical Rating Scale (WI NRS)

Time Frame: Baseline, Week 12

The WI-NRS is a patient-reported outcome (PRO) instrument consisting of a single question that asks participants to rate the severity of their worst itch over a defined period. The score range is from 0 (no itch) to 10 (worst imaginable itch). Higher scores indicate worse itch severity.

Secondary Outcomes

Proportion of participants achieving ≥4 point reduction from baseline in WI NRS(Baseline, Week 4)
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)(Week 12)
Proportion of participants achieving Patient Global Impression of Severity (PGIS) score of 0 (none) or 1 (mild)(Week 24)
Change from baseline in Pruritus-related Sleep Disturbance Numerical Rating Scale (SD-NRS)(Week 12)
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)(Up to Week 52)

Investigators

Sponsor

Novartis Pharmaceuticals

Sponsor Class

Industry

Responsible Party

Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Recruiting

Phase 3

A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)Chronic Pruritus of Unknown Origin

NCT07700056Novartis Pharmaceuticals180

Recruiting

Phase 3

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSHidradenitis Suppurativa

NCT07665437Novartis Pharmaceuticals710

Recruiting

Phase 3

A 52-week Study of Remibrutinib in IgE-mediated Food AllergyIgE-Mediated Food AllergyPeanut AllergyCow Milk AllergyEgg Allergy

NCT07768371Novartis Pharmaceuticals576

Not yet recruiting

Phase 3

A study to examine usefulness and safety of remibrutinib in patients with generalized myasthenia gravis.

CTRI/2025/07/092102Novartis Healthcare Pvt Ltd180

Recruiting

Phase 3

52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in comparison to placebo with omalizumab as active control in adult patients with CSU and inadequate response to H1-antihistamine and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.

2022-502161-19-00Novartis Pharma AG214